$3.83 Billion in Sales Expected for DaVita HealthCare Partners Inc. (DVA) This Quarter
Equities research analysts expect DaVita HealthCare Partners Inc. (NYSE:DVA) to post $3.83 billion in sales for the current quarter, according to Zacks. Five analysts have provided estimates for DaVita HealthCare Partners’ earnings, with the highest sales estimate coming in at $3.88 billion and the lowest estimate coming in at $3.79 billion. DaVita HealthCare Partners posted sales of $3.72 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 3%. The business is expected to report its next quarterly earnings report after the market closes on Tuesday, August 1st.
On average, analysts expect that DaVita HealthCare Partners will report full-year sales of $3.83 billion for the current year, with estimates ranging from $15.06 billion to $15.47 billion. For the next fiscal year, analysts expect that the firm will post sales of $15.92 billion per share, with estimates ranging from $15.63 billion to $16.32 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow DaVita HealthCare Partners.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 2nd. The company reported $0.79 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.82 by $0.03. DaVita HealthCare Partners had a net margin of 8.28% and a return on equity of 14.85%. The business had revenue of $3.70 billion during the quarter, compared to analysts’ expectations of $3.69 billion.
DVA has been the subject of several recent research reports. Jefferies Group LLC set a $70.00 price target on DaVita HealthCare Partners and gave the company a “buy” rating in a research note on Friday, May 26th. Zacks Investment Research raised DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a research note on Tuesday, April 18th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $62.00 price target on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th. TheStreet raised DaVita HealthCare Partners from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Finally, BidaskClub cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research note on Saturday, July 8th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $69.50.
In related news, Director Charles Berg sold 8,414 shares of the company’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $65.80, for a total value of $553,641.20. Following the completion of the transaction, the director now directly owns 34,719 shares in the company, valued at $2,284,510.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Javier Rodriguez sold 1,294 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $66.21, for a total value of $85,675.74. Following the completion of the transaction, the chief executive officer now owns 99,111 shares of the company’s stock, valued at $6,562,139.31. The disclosure for this sale can be found here. Insiders sold 22,702 shares of company stock valued at $1,495,492 over the last 90 days. 2.00% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parametrica Management Ltd bought a new position in DaVita HealthCare Partners during the first quarter valued at about $237,000. Bank of Montreal Can raised its position in DaVita HealthCare Partners by 2.8% in the first quarter. Bank of Montreal Can now owns 304,431 shares of the company’s stock valued at $20,691,000 after buying an additional 8,196 shares in the last quarter. Murphy Capital Management Inc. raised its position in DaVita HealthCare Partners by 137.7% in the first quarter. Murphy Capital Management Inc. now owns 11,566 shares of the company’s stock valued at $786,000 after buying an additional 6,700 shares in the last quarter. National Pension Service raised its position in DaVita HealthCare Partners by 6.2% in the first quarter. National Pension Service now owns 155,161 shares of the company’s stock valued at $10,629,000 after buying an additional 9,075 shares in the last quarter. Finally, Gulf International Bank UK Ltd raised its position in DaVita HealthCare Partners by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 50,891 shares of the company’s stock valued at $3,459,000 after buying an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 81.93% of the company’s stock.
DaVita HealthCare Partners (NYSE DVA) traded down 0.08% on Wednesday, reaching $65.16. 95,076 shares of the company traded hands. The stock has a market capitalization of $12.68 billion, a price-to-earnings ratio of 10.70 and a beta of 0.89. DaVita HealthCare Partners has a 52-week low of $54.50 and a 52-week high of $78.40. The firm has a 50 day moving average price of $64.82 and a 200 day moving average price of $66.03.
COPYRIGHT VIOLATION NOTICE: “$3.83 Billion in Sales Expected for DaVita HealthCare Partners Inc. (DVA) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/19/3-83-billion-in-sales-expected-for-davita-healthcare-partners-inc-dva-this-quarter.html.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.